Landscape of chromatin remodeling gene alterations in endometrial carcinoma.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
05 2023
Historique:
received: 13 11 2022
revised: 01 02 2023
accepted: 15 03 2023
pmc-release: 01 05 2024
medline: 19 5 2023
pubmed: 24 3 2023
entrez: 23 3 2023
Statut: ppublish

Résumé

Chromatin remodeling genes (CRGs) encode components of epigenetic regulatory mechanisms and alterations in these genes have been identified in several tumor types, including gynecologic cancers. In this study, we sought to investigate the prevalence and clinicopathological associations of CRG alterations in endometrial carcinoma (EC). We performed a retrospective analysis of 660 ECs sequenced using a clinical massively parallel sequencing assay targeting up to 468 genes, including 25 CRGs, and defined the presence of somatic CRG alterations. Clinicopathologic features were obtained for all cases. Immunohistochemical interrogation of ARID1A and PTEN proteins was performed in a subset of samples. Of the 660 ECs sequenced, 438 (66.4%) harbored CRG alterations covered by our panel. The most commonly altered CRG was ARID1A (46%), followed by CTCF (21%), KMT2D (18%), KMT2B (17%), BCOR (16%), ARID1B (12%) and SMARCA4 (11%). We found that ARID1A genetic alterations were preferentially bi-allelic and often corresponded to altered ARID1A protein expression in ECs. We further observed that ARID1A alterations were often subclonal when compared to PTEN alterations, which were primarily clonal in ECs harboring both mutations. Finally, CRG alterations were associated with an increased likelihood of myometrial and lymphovascular invasion in endometrioid ECs. CRG alterations are common in EC and are associated with clinicopathologic features and likely play a crucial role in EC.

Identifiants

pubmed: 36958196
pii: S0090-8258(23)00145-2
doi: 10.1016/j.ygyno.2023.03.010
pmc: PMC10192087
mid: NIHMS1884502
pii:
doi:

Substances chimiques

Chromatin 0
SMARCA4 protein, human EC 3.6.1.-
DNA Helicases EC 3.6.4.-
Nuclear Proteins 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-64

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest B.W. reports ad hoc membership of the scientific advisory board of REPARE Therapeutics, outside the current work. R.A.S. reports medical legal consultant (Shook Hardy Bacon); royalties from Modern Pathology/USCAP, AFIP/ARP, Cambridge Univ Press and Springer publishing. C.A. reports membership of advisory boards/ personal fees from Tesaro, Eisai/Merck, Mersana Therapeutics, Roche/Genentech, Abbvie, AstraZeneca/Merck, Repare Therapeutics, and grants from Clovis, Genentech, AbbVie, Astra Zeneca, all outside the submitted work. N.R. Abu-Rustum reports Stryker/ Novadaq and GRAIL grants paid to the institution, outside the current study. The remaining authors have no relevant conflicts.

Références

Genome Biol. 2019 Nov 20;20(1):245
pubmed: 31747960
Nat Rev Clin Oncol. 2020 Jul;17(7):435-448
pubmed: 32303701
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Mod Pathol. 2016 Mar;29(3):302-14
pubmed: 26743474
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Nat Rev Cancer. 2015 Jun;15(6):334-46
pubmed: 25998713
Hum Mutat. 2012 Jan;33(1):100-3
pubmed: 22009941
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Gastroenterology. 2008 Oct;135(4):1079-99
pubmed: 18773902
Nat Commun. 2019 Aug 7;10(1):3554
pubmed: 31391455
Oncotarget. 2017 Jul 11;8(51):89315-89325
pubmed: 29179522
Cell. 2007 Feb 23;128(4):693-705
pubmed: 17320507
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Cancer Res. 2011 Nov 1;71(21):6718-27
pubmed: 21900401
EMBO Rep. 2012 Jun 29;13(7):619-30
pubmed: 22688965
Cell. 2009 Jun 26;137(7):1194-211
pubmed: 19563753
Nat Rev Mol Cell Biol. 2015 Sep;16(9):519-32
pubmed: 26296162
In Vivo. 2019 May-Jun;33(3):659-667
pubmed: 31028182
Genome Biol. 2016 Dec 16;17(1):261
pubmed: 27986087
Hum Pathol. 2013 Jan;44(1):103-9
pubmed: 22939958
Mol Cell. 2009 May 15;34(3):271-84
pubmed: 19450526
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3458-62
pubmed: 20142505
Int J Cancer. 2017 Apr 1;140(7):1551-1563
pubmed: 27997699
Mod Pathol. 2013 Mar;26(3):428-34
pubmed: 23080032
Cancer Genet. 2015 Jun;208(6):345-50
pubmed: 25963524
Nat Methods. 2014 Apr;11(4):396-8
pubmed: 24633410
Nat Genet. 2016 Aug;48(8):848-55
pubmed: 27348297
Gynecol Oncol. 2018 Sep;150(3):426-431
pubmed: 30126589
Histopathology. 2020 Jan;76(1):64-75
pubmed: 31846533
Cell Res. 2011 Mar;21(3):381-95
pubmed: 21321607
Mod Pathol. 2012 Jun;25(6):885-92
pubmed: 22301703
Curr Opin Genet Dev. 2014 Feb;24:8-15
pubmed: 24657531
Br J Haematol. 2011 Jan;152(1):3-12
pubmed: 21083654
J Cell Biochem. 2017 Dec;118(12):4517-4525
pubmed: 28466574
J Pathol. 2011 Jul;224(3):328-33
pubmed: 21590771
Am J Surg Pathol. 2018 Jan;42(1):76-83
pubmed: 28863077
Curr Opin Genet Dev. 2013 Apr;23(2):89-95
pubmed: 23270812
Clin Cancer Res. 2021 May 1;27(9):2613-2623
pubmed: 33602681
JCO Precis Oncol. 2017;2017:
pubmed: 30211344
Am J Surg Pathol. 2018 May;42(5):604-615
pubmed: 29300189
Science. 2010 Oct 8;330(6001):228-31
pubmed: 20826764
Genes Dev. 2000 Jul 15;14(14):1810-23
pubmed: 10898795
Nat Cell Biol. 2019 Feb;21(2):152-161
pubmed: 30602726
Cancer Lett. 2020 Nov 1;492:162-173
pubmed: 32858102
Mol Oncol. 2012 Dec;6(6):611-9
pubmed: 23127546
BMC Bioinformatics. 2018 Dec 19;19(1):534
pubmed: 30567491
Curr Protein Pept Sci. 2016;17(5):401-10
pubmed: 26796306
Curr Opin Genet Dev. 2013 Apr;23(2):185-90
pubmed: 23274160
Chem Rev. 2015 Mar 25;115(6):2255-73
pubmed: 25495456
Genom Comput Biol. 2017;3(2):
pubmed: 31245531
Am J Surg Pathol. 2011 May;35(5):625-32
pubmed: 21412130
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Biochem J. 2004 Oct 15;383(Pt 2):319-25
pubmed: 15170388
Proc Natl Acad Sci U S A. 2008 May 6;105(18):6656-61
pubmed: 18448678
Nat Commun. 2020 Jun 1;11(1):2717
pubmed: 32483112
Adv Genet. 2010;70:57-85
pubmed: 20920745
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027
Nat Genet. 2014 Mar;46(3):225-233
pubmed: 24487277
Biochim Biophys Acta. 2005 Jan 11;1681(2-3):59-73
pubmed: 15627498
Genome Res. 2012 Nov;22(11):2120-9
pubmed: 23028188
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821

Auteurs

Amir Momeni-Boroujeni (A)

Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.

Chad Vanderbilt (C)

Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.

Elham Yousefi (E)

Department of Pathology and Cell Biology, Columbia University Irvine Medical Center, New York, NY, United States of America.

Nadeem R Abu-Rustum (NR)

Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.

Carol Aghajanian (C)

Departments of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.

Robert A Soslow (RA)

Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.

Lora H Ellenson (LH)

Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.

Britta Weigelt (B)

Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.

Rajmohan Murali (R)

Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America. Electronic address: MuraliR@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH